Nick Hardman
About Nick Hardman
Nick Hardman is the Group Cleaning Validation Manager at Dechra Pharmaceuticals PLC, where he has worked since 2020. He holds a PhD in Molecular Genetics from the University of Wales, Bangor, and has extensive experience in validation roles across various companies, including GSK and Siemens.
Work at Dechra Pharmaceuticals
Nick Hardman has been serving as the Group Cleaning Validation Manager at Dechra Pharmaceuticals PLC since 2020. In this role, he has developed and implemented global cleaning validation practices and procedures. He is responsible for cross contamination control strategies and effective cross contamination risk management. Additionally, he plays a key role in building internal validation capability across multiple sites within the organization. Hardman also serves as the primary manufacturing contact for FDA inspections, corporate audits, and customer audits.
Education and Expertise
Nick Hardman studied at the University of Wales, Bangor, where he focused on Molecular Genetics and earned a Doctor of Philosophy (PhD) from 1992 to 2000. His educational background provides a strong foundation for his expertise in validation processes and cross contamination control within the pharmaceutical industry.
Professional Background
Before joining Dechra Pharmaceuticals, Nick Hardman held various positions in the pharmaceutical sector. He worked as a Validation Coordinator at GSK Ulverston from 2017 to 2018. His previous roles include Process Specialist, Process Manager & Technical Lead, and Deputy Shift Supervisor, spanning from 2000 to 2013. He also served as a Validation Engineer at GSK from 2019 to 2020 and as a Cleaning Validation Specialist at Dechra Pharmaceuticals from 2018 to 2019.
Career Achievements
During his career, Nick Hardman has contributed significantly to the field of cleaning validation. He has developed and implemented practices that enhance compliance and efficiency in cleaning validation processes. His role in managing cross contamination risks and building validation capabilities across multiple sites reflects his commitment to maintaining high standards in pharmaceutical manufacturing.